Millions of parents
Missing millions of moments
Missing due to lack of research and care for people with myalgic encephalomyelitis
Do not let them miss a moment more
#MillionsMissing
Millions of parents
Missing millions of moments
Missing due to lack of research and care for people with myalgic encephalomyelitis
Do not let them miss a moment more
#MillionsMissing
We were dancers
We were athletes
We were adventurers
We had careers
We had plans
We had dreams
We had lives
Now we are the #MillionsMissing
Sign up to show you are missing from your lives and:
Check the calendar for events in other places
Analysis of the 2008 Cochrane review of cognitive behavioural therapy for chronic fatigue syndrome shows that seven patients with mild chronic fatigue syndrome need to be treated for one to report a small, short-lived subjective improvement of fatigue. This is not matched by an objective improvement of physical fitness or employment and illness benefit status.
Most studies in the Cochrane review failed to report on safety or adverse reactions. Patient evidence suggests adverse outcomes in 20 per cent of cases. If a trial of a drug or surgical procedure uncovered a similar high rate, it would be unlikely to be accepted as safe. It is time to downgrade cognitive behavioural therapy to an adjunct support-level therapy, rather than a treatment for chronic fatigue syndrome.
Our analysis of the RCTs included in the Cochrane CBT review identified 12 areas of concern. These included potentially selecting patients who do not have the disease. A failure to exclude patients with comorbid depression and anxiety, even though CBT is the most effective treatment for both, as a meta-analysis by Tolin (2012) found. One of the other important problems of the trials and the review itself was the use of subjective primary outcomes even though in non-blinded trials, self-reported outcomes can
produce highly inflated estimates of treatment-related benefits contrary to objective outcome measures (Wilshire et al., 2018b). Moreover, it is unclear why the trials relied
on subjective primary outcomes when the basis of CBT for CFS is that patients suffer from false illness beliefs and they do not know how to interpret their symptoms correctly.
The flaws in the review and the trials, as discussed at the beginning of this article, all created a bias in favour of the intervention. It was therefore crucial to demonstrate
accompanying improvement on more objective measures yet these did not yield significant treatment effects. Most notably, treatment did not affect fitness.
Our analysis shows that CBT did not improve the quality of life scores either, in a disease where these scores are much lower than in the general population and the lowest compared to 20 other chronic illnesses which included stroke, lung cancer and MS (Falk Hvidberg et al., 2015). Nothing has changed in that respect compared to the 1996
health status report (Komaroff et al., 1996) despite the widespread use and promotion of CBT and GET as effective treatments, which provides indirect evidence of their inefficacy…
Real-world application of CBT in NHS CFS clinics shows equally poor results. Moreover, patients who had been treated with CBT and GET in these clinics had less improvement in fatigue at 12 months than those who had been offered activity management (Crawley et al., 2013).
This is in line with the outcomes of patient surveys which have repeatedly shown that rest and activity management (pacing) are the most helpful, with CBT and GET among the least effective therapies (Kirke, 2017). Just 3 per cent of CFS patients report no longer having CFS after NHS treatment; 2–5 years after the initial assessment, this was 5.7 per
cent (Collin and Crawley, 2017), which is essentially the same as the naturally occurring recovery rate of 5 per cent (Cairns and Hotopf, 2005).
The impact of CFS results in disruptions to productivity and meaningful occupation, which is often not the case with other conditions (Roberts, 2018). An influential systematic review by Cairns and Hotopf concluded in 2005 that because there is increasing evidence for the effectiveness of CBT and GET, that ‘Medical retirement should be postponed until a trial of such treatment has been given’.
Yet our reanalysis, just like the reanalysis of the Cochrane GET review (Vink and Vink-Niese, 2018b), shows that CBT and GET do not improve the number of hours worked or sickness and disability benefit status.
1. For clinicians
If a skilled CBT therapist is available, who acknowledges the severity of this debilitating multisystem disease, then offering CBT to patients as an adjunct support therapy is
something to consider. Especially when patients also suffer from a comorbid depression or anxiety disorder or have problems adapting to a life of disability/dependence on others. The findings of this reanalysis do not encourage to instigate treatment programmes of CBT for people with CFS as has been the case so far.
2. For policymakers, occupational health services and illness benefit assessors
This reanalysis shows that CBT does not lead to an improvement of fitness, a reduction of the number of patients on sickness and disability benefits or an improvement of employment status. Forcing patients to undergo this expensive treatment as a requirement to be eligible for illness benefits or medical retirement causes a lot of stress for
patients and their families without any benefits to patients and society.
3. For people with CFS
For many patients with CFS, becoming involved in a CBT programme has been compulsory to be eligible for illness benefits or medical retirement. Based on the notion that if they did not want to be treated with CBT, they were after secondary gains and not motivated to get better. This reanalysis however shows that CBT does not lead to significant improvement in quality of life. Nor does it lead to an improvement in fitness or employment status or reduction of the number of patients receiving sickness and disability
benefits.
In any event, people with CFS, if offered this therapy, should know that any effect on fatigue is likely to be short-lived and small in degree. Also, that six out of seven patients will undergo the treatment without any benefit andone in five will suffer negative consequences because of it. However, if patients suffer from a comorbid depression or
anxiety disorder, or they need help coping with a debilitating illness, then it would be wise to consider help or support from a qualified and knowledgeable psychologist.
Online blog Broadly highlights the fact that one in five children with ME are investigated by social services, with some even being forcibly placed in a hospital or foster homes, with destructive effects on their health.
Social services can threaten families of children with Chronic Fatigue, by Natasha Wynarczyk, May 2 2019
In the article WAMES’ medical advisor Dr Nigel Speight gives his view of the situation:
This is approaching a “national scandal,” according to Dr. Nigel Speight, a pediatrician from the North East of England who specializes in ME. Throughout his 30-year career, he has helped large numbers of families fight child protection cases where children with the condition have been at risk of removal from their parents. He says that anyone—including the child’s doctor, their teacher, and even a neighbor or relative—can get social services involved, and the decision to take a family to court often rests with people who have never even met the children…
“Many doctors these days don’t take proper case histories,” Speight says. “They are focused on ordering tests—but you can diagnose ME in an hour if you properly investigate the patient’s history. Either through ignorance or wilful avoidance, many doctors fail to make the diagnosis.”
“you can diagnose ME in an hour if you properly investigate the patient’s history”
“In some cases of GET, children with ME are being told to increase their energy levels by 10 per cent a week—if I did this, I’d be an Olympic athlete,” Speight says. He adds that when families complain that the child is being made more ill, they can be told to “push through the pain.”
“One of the most heartbreaking cases I’ve dealt with was an eight-year-old girl who was forced to have GET,” he adds. “Her parents were told that if they didn’t comply, she’d be taken away [by social services].
“Her parents reluctantly allowed her to be admitted to hospital where she was given vigorous physiotherapy for several months. She was able to walk before being admitted, but after she deteriorated to the extent that she became bed-bound and needed to be fed via a tube.”
He adds that while he may have an “unduly pessimistic view” of the situation due to his involvement in many of the worst cases around the UK, these may be the tip of the iceberg. For every family who have involvement with social services, he says, there are many others subjected to “disbelief and pressure, especially around school attendance”.
ME Awareness week 6th – 12th May 2019
Produced by Broken Battery, 2 May 2019
1 in 5 parents face child protection proceedings, patients have been sectioned and abused, NHS treatments make over 50% of patients worse, biomedical research has been pitiful. A global health scandal that has been ignored for over 30 years.
ME has a lower quality of life than HIV/AIDS, Stroke, Parkinsons, Multiple Sclerosis [1], but is one of the most misunderstood diseases. 80% of doctors think its psychosomatic [2].
Misunderstanding has led to 1 in 5 parents face child protection proceedings [3]. A recent example is an April 2019 iNews article where Georgia Whyard’s teachers said she had ‘school phobia’ despite having an official diagnosis of myalgic encephalomyelitis [4].
Misunderstanding has led to patients being sectioned. In 2003 police forced entry into Sophia Mirza’s mother’s home, sectioned, and forced Sophia to a mental hospital. After being released Sophia had severely deteriorated and later died. An independent Neuropathologist found Sophia’s spine contained massive infection and Sophia was the first patient to have ME listed as her cause of death [5].
Misunderstanding has led to abuse, Ean Proctor was removed from his home against his parents’ wishes and hospitalized under a “Place of Safety Order.” While in the hospital his health deteriorated as he was subjected to inhumane treatments: being placed into a therapy pool to force him to use his arms to swim, although he was unable to and would sink underwater; [6]
Many ME/CFS patients have been harmed by Graded Exercise Therapy. Over 50% of patients consistently report a worsening of their condition in an analysis of 18000 patients from 10 surveys from multiple countries [7]. Many have been made permanently disabled.
The PACE Trial has been widely discredited [8] Over 100 scientists and over 80 international charities (Nearly every one) signed an open letter asking for the trial to be independently reanalysed [9]. Former science teacher Carol Monaghan MP described PACE as “one of the greatest medical scandals of the 21st century” and said “As a scientist, I am appalled by the methods used in the trial, which included changing the parameters and success criteria midway through the study. This has been widely discredited in the research community” Over 30 MPs have signed up to the MAIMES Campaign calling for an investigation into The PACE Trial [10].
ME receives a disproportionally small amount of UK research funding given the prevalence of the condition. Despite the disease burden, the level of research spend per ME/CFS patient is considerably lower than in other illnesses. MS, for example, receives approximately 20 times more funding worldwide despite 2.5 times less prevalent than ME [11]. Read references & credits
#StopIgnoringME #TimeForUnrestWales #HelpNHSbeMEaware
#BeMEaware #WAMESMECFS
Purpose:
Studies to determine epigenetic changes associated with myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) remain scarce; however, current evidence clearly shows that methylation patterns of genomic DNA and noncoding RNA profiles of immune cells differ between patients and healthy subjects, suggesting an active role of these epigenetic mechanisms in the disease.
The present study compares and contrasts the available ME/CFS epigenetic data in an effort to evidence overlapping pathways capable of explaining at least some of the dysfunctional immune parameters linked to this disease.
Methods:
A systematic search of the literature evaluating the ME/CFS epigenome landscape was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria. Differential DNA methylation and noncoding RNA differential expression patterns associated with ME/CFS were used to screen for the presence of transposable elements using the Dfam browser, a search program nurtured with the Repbase repetitive sequence database and the RepeatMasker annotation tool.
Findings:
Unexpectedly, particular associations of transposable elements and ME/CFS epigenetic hallmarks were uncovered. A model for the disease emerged involving transcriptional induction of endogenous dormant transposons and structured cellular RNA interactions, triggering the activation of the innate immune system without a concomitant active infection.
Implications:
Repetitive sequence filters (ie, RepeatMasker) should be avoided when analyzing transcriptomic data to assess the potential participation of repetitive sequences (“junk repetitive DNA”), representing >45% of the human genome, in the onset and evolution of ME/CFS. In addition, transposable element screenings aimed at designing cost-effective, focused empirical assays that can confirm or disprove the suspected involvement of transposon transcriptional activation in this disease, following the pilot strategy presented here, will require databases gathering large ME/CFS epigenetic datasets.
Introduction: An increasing number of patients present with multiple symptoms affecting many organs including the brain due to multiple mediators released by mast cells. These unique tissue immune cells are critical for allergic reactions triggered by immunoglobulin E (IgE), but are also stimulated (not activated) by immune, drug, environmental, food, infectious, and stress triggers, leading to secretion of multiple mediators often without histamine and tryptase.
The presentation, diagnosis, and management of the spectrum of mast cell disorders are very confusing. As a result, neuropsychiatric symptoms have been left out, and diagnostic criteria made stricter excluding most patients.
Areas covered: A literature search was performed on papers published between January 1990 and November 2018 using MEDLINE. Terms used were activation, antihistamines, atopy, autism, brain fog, heparin, KIT mutation, IgE, inflammation, IL-6, IL-31, IL-37, luteolin, mast cells, mastocytosis, mediators, mycotoxins, release, secretion, tetramethoxyluteolin, and tryptase.
Expert opinion: Conditions associated with elevated serum or urine levels of any mast cell mediator, in the absence of comorbidities that could explain elevated levels, should be considered ‘Mast Cell Mediator Disorders (MCMD).’ Emphasis should be placed on the identification of unique mast cell mediators, and development of drugs or supplements that inhibit their release.
Article abstract:
The forerunner of what is today termed myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) was described by the CDC in 1934. At the present time, we still do not know its cause and or how to detect it by routine clinical laboratory tests. In consequence the pathological nature of ME/CFS has been overlooked and the disease has been stigmatized by being mislabeled as psychosomatic or somatoform illness.
Such misperceptions of the disease have led to sub-standard research exploration of the disease and minimal to absent patient care. A 2015 Institute of Medicine report on the illness declared ME/CFS a disease affecting up to 2.5 million Americans and chastised the U.S. government for doing little to research the disease and to support its patients.
Clinicians who currently treat this disease declare it to be more devastating than HIV/AIDS. A comparison of the histories of the two diseases, an examination of the current status of the two diseases, and a listing of the accomplishments that would be needed for ME/CFS to achieve the same level of treatment and care as currently experienced by patients with HIV/AIDS is provided.
Wales online reports:
Since June last year, Natalie Price has spent almost her entire existence inside the four walls of her Cardiff bedroom.
Her extreme sensitivity to light and sound means she often needs to be in complete darkness wearing noise-reducing earplugs.
She is so easily exhausted that she is no longer able to have long conversations, read a book or even watch television.
“The hardest part of it all is the fact I can only spend around 30 minutes with her every day,” said her fiancé Jonathan Vaughan, who is now Natalie’s carer.
“Any longer than that and she’s overstimulated.
“She can only see her friends for about 20 minutes once a month. They will come up to her darkened bedroom and speak to her, but often she can’t reply very much.
“I’ve basically had to stand by and watch her go from a very active, determined person into someone who can’t even eat a bowl of soup because it requires too much energy in her arms.” …….
After speaking to an ME specialist in England, Jonathan has now set up a GoFundMe page in a bid to get Natalie brain photobiomodulation (bPBM) therapy privately.
It works by feeding red light directly to the brain which then boosts the neurons’ ability to create energy.
Jonathan said there is only a 5% chance of Natalie making a full recovery from her illness
“Natalie is at the moment akin to a plant in a dark room that is unable to photosynthesize as her cells cannot generate energy,” said Jonathan.
“A treatment like bPBM for Natalie could be like moving that plant outside into the sunshine.
“These are treatments that have shown promise in trials. Although bPBM is used more for dementia at the moment, trials regarding ME have shown to increase cognitive ability.
“To even get Natalie back to a place where she can watch an episode of something on TV once a day would be miraculous for us.
“Frankly, she has absolutely no quality of life at the moment and we will do anything to try and claw at least some of it back for her. Her entire life has just stopped.”
If you would like to donate to Natalie go to www.gofundme.com/let039s-give-natalie-some-of-her-life-back
Read the full Wales online article by Mark Smith, 29 April 2019: ‘My fiancée was so active, she loved running and life – now she lives in darkness and near silence’ Natalie Price, 28, can’t eat or clean herself due to her incurable condition
Mirror, 30 Apr 2019: Woman, 28, goes from keen runner to year in dark room because of severe disorder
A review of research lists the conditions PBM therapy has been trialled for.
Health rising: Mitochondrial Repair Using Light Therapy?